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Abstract:  Cardiovascular disease is a leading cause of death among patients with end stage renal failure. Animal   
models have played a crucial role in teasing apart the complex pathological processes involved. This review discusses  
the principles of using animal models, the history of their use in the study of renal hypertension, the controversies   
arising from experimental models of non-hypertensive uraemic cardiomyopathy and the lessons learned from these   
models, and highlights important areas of future research in this field, including de novo cardiomyopathy secondary to  
renal transplantation. 
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INTRODUCTION 
  Animal models have been invaluable in the study of hu-
man disease. In addition to the anatomical and histological 
characteristics humans share with other species, human dis-
eases can be reproduced in these species using pharmacol-
ogical, surgical or genetic manipulation. Experimentation 
still provides the best evidence for disease causation, and 
only with this evidence can clinical science proceed to de-
veloping treatments. However, experimentation is often not 
possible or ethical in human subjects, and thus without these 
animal models the advancement in knowledge of the patho-
physiology of disease would come to a standstill. 
  In few other specialities have experimental models been 
as crucial to the study of pathology as in renal medicine. The 
way in which kidneys succumb to disease and the develop-
ment of renal failure involves complex interactions between 
numerous different systems, mediated by a multitude of 
chemicals. Current understanding of renal disease is merely 
the tip of the metaphorical iceberg. The history of renal pa-
thology is plagued by controversy, and nowhere is this more 
evident than in the development of cardiovascular disease in 
patients with chronic renal failure. Impairment of renal func-
tion increases the risk of cardiac disease to 15-20 times that 
of individuals with normal renal function [1, 2]. The result is 
that cardiac disease causes 40% of deaths in patients on di-
alysis [3]. From the Goldblatt kidney to modern molecular 
studies, this review focuses on the use of experimental mod-
els in the study of the relationship between renal and cardio-
vascular disease, and highlights the questions that remain 
unanswered. 
CHOOSING AN ANIMAL MODEL  
  It is not possible to perform a systematic review of all  
the papers published on animal models in renal and   
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cardiovascular disease, as the area is extremely broad. The 
aim of this review is, therefore, to summarise the key meth-
ods in the study of renal disease, and highlight what has been 
learned from animal models on the subject of renal disease 
and the cardiovascular system, focusing on the key experi-
ments. 
  That said, following on from the estimates by Pinto et al. 
[4] of the number of publications on hypertension per spe-
cies, a search was performed on Pubmed for “renal and car-
diovascular disease model” for various species, in order to 
gain some insight into which animals are most commonly 
used in this field, bearing in the mind the crudeness of such a 
search, as previously emphasised [4]. The results are shown 
in Table 1. 
Table  1.  Publications on Animal Models of Renal and   
Cardiovascular Disease 
Species  Number of References (No Date Limits) 
Rat   1830 
Mouse 416 
Pig 325 
Dog 275 
Rabbit 173 
Cat 28 
Baboon 15 
Cattle 15 
Guinea pig  12 
Hamster 10 
(Source: Pubmed 16 November 2009). 
  Many different animals have been used to replicate hu-
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required from the experiment. Choosing the animal model is 
a process in which cost, animal welfare and practical suit-
ability must all be considered. All species have both advan-
tages and disadvantages with regards to this process. 
  An ideal animal model should have similar anatomy and 
physiology to humans; results of experimentation should be 
readily transferable to humans; similar pathological findings 
to humans should be evident; and interventions to reproduce 
human pathological findings in the animal should be techni-
cally achievable without producing pain or suffering. 
Rat Models 
  As can be seen from Table 1, the rat is the most com-
monly used model in the study of renal and cardiovascular 
disease. Types include Wistar, Sprague-Dawley, Fawn-
hooded, Fisher and Lewis. The advantages of using rat mod-
els are that they are inexpensive and have short gestation 
periods (59-72 days) [5], meaning large sample sizes can be 
achieved in a short space of time [6]. The disadvantages are 
predominantly due to the anatomical, physiological and 
pathological differences between rat and man. With respect 
to cardiac physiology, rat myocardium has a shorter action 
potential and the sodium calcium pump (Na
+/Ca
2+ pump)   
has a smaller role [6]. Furthermore, the myosin isoforms are 
different, heart rates are faster, and the force-frequency rela-
tionship is inversed. Doggrell and Brown highlight some of 
the important pathological differences between rat and man 
relating to cardiovascular disease: that these diseases are 
slowly developing in man, compared to the rapid onset im-
posed upon laboratory rats; and that these diseases are more 
common in older humans, but laboratory rats are usually 
young [7]. In addition, atherosclerosis is seldom seen in rats 
[4], whereas this process plays an important role in human 
cardiovascular disease.  
Mouse Models 
  The mouse is the most commonly used animal in labora-
tory research in general [5]. Mouse models share similar 
advantages to rats, with the addition that the karyotypes of 
the many inbred strains and outbred stocks are known, mak-
ing it useful for genetic modification, such as gene knockout 
models. However, mice are smaller than rats, making surgi-
cal interventions more technically difficult.  
Rabbit Models 
  Rabbits are larger than rats and mice and less expensive 
than dogs and pigs, and share certain cardiac physiological 
features with humans: rabbit hearts have a predominant beta-
myosin heavy chain isoform [6], and a similar sarcoplasmic 
reticulum and force-frequency relationship to humans. 
Large Animal Models 
  Large animals such as dogs and pigs are used to study 
cardiac function and ventricular volumes with greater accu-
racy than would be achieved in smaller animals [6], and al-
low long-term interventional measures to be used to produce 
physiological changes. Dogs are particularly useful as the 
cardiac electrophysiology is similar to humans, with domi-
nance of the beta-myosin heavy chain isoform as in rabbits. 
Pigs also have similar anatomy and physiology to humans. 
The disadvantages of using large animals are primarily cost, 
long gestation and growth times, and the extensive resources 
required to provide adequate care. 
RENAL HYPERTENSION: THE GOLDBLATT   
KIDNEY AND BEYOND 
  Hypertension has a complex, multifactorial aetiology, the 
study of which is further complicated by the arbitrary cut-off 
that separates the pathological from the norm. The most 
common type of this condition is so-called essential hyper-
tension, which probably represents an interplay of various 
genes, via their diverse alleles and levels of penetrance. Of-
ten these facts are taken for granted, and what is less com-
monly considered is the controversy that mars the history of 
hypertension research, which centres on the relationship be-
tween hypertension and the kidney. There are several infor-
mative reviews written on the subject of animal models in 
hypertension [4, 8], including the use of endocrinological, 
metabolic, diet-induced, salt-induced and genetic models of 
essential hypertension, as well as the spontaneously hyper-
tensive rat. This section will thus briefly review the history 
of the use of experimental models in renal hypertension, as 
the methods and theories learned from these experiments 
have contributed greatly to the work performed on non-
hypertensive renal causes of cardiovascular disease. 
  Harry Goldblatt (1891-1977), born and educated in Can-
ada, was a Professor of Experimental Pathology at the West-
ern Reserve University School of Medicine in Cleveland, 
Ohio [9, 10]. Throughout his career, he had been interested 
in the role of the kidney in the development of hypertension, 
and it was his work that led to the use of the eponymous 
Goldblatt kidney. The studies of Goldblatt and his colleagues 
on experimental hypertension from 1934 onwards, were a 
landmark series of experiments that paved the way for future 
methods of inducing persistent hypertension in laboratory 
animals [11-14]. In the first of these experiments, the authors 
used a clamp to constrict the renal arteries of dogs, produc-
ing renal ischaemia and rendering the dogs hypertensive for 
several months [11]. Unilateral renal ischaemia produced 
hypertension which was transient, partly due to the devel-
opment of a collateral circulation to the affected kidney 
which restored blood flow. Bilateral moderate constriction of 
renal arteries produced hypertension with no renal dysfunc-
tion, while nearly complete bilateral constriction resulted in 
very high blood pressures and severe renal dysfunction. An-
other method of producing persistent hypertension was to 
constrict one renal artery, and once the blood pressure was 
elevated, to remove the contralateral kidney. Goldblatt et al. 
also showed that hypertension could arise from constriction 
of the suprarenal aorta [13]. Goldblatt subsequently showed 
that in other animals, including monkeys, sheep, rabbits and 
rats, constriction of one renal artery was sufficient to pro-
duce hypertension lasting many months [12, 14-16]. 
  The clamps used by Goldblatt et al. subsequently evolved 
into clips, with Pickering and Prinzmetal using a silver clip 
to constrict rabbit arteries [17]. These silver clips were used 
by Wilson and Byrom on rats to study accelerated (malig-
nant) hypertension [18]. It was later shown that changing the 
clip diameter could produce different degrees of hyperten-
sion in the Wistar rat [19], and that the onset of hypertension 
could be gradual and chronic, with a plateau at two weeks. In 
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decrease [8]. These methods continue to be used; Capasso  
et al. applied a unilateral silver clip to the renal arteries of 
Fischer rats to study hypertensive left ventricular failure 
[20]. To study cardiac remodelling, Brilla et al. used a modi-
fied two-kidney, one-clip model by subjecting Sprague-
Dawley rats to abdominal aortic banding with unilateral re-
nal artery constriction, producing unilateral renal atrophy 
[21]. Dobrian et al. used the one-kidney, one-clip method in 
Wistar rats, and uninephrectomised rats as normotensive 
controls, to show that blood pressure could be well con-
trolled with the synergistic use of an angiotensin II blocker 
and a superoxide dismutase mimetic [22]. Both the two-
kidney, one
 clip method [23, 24] and the one-kidney, one-
clip [24] methods have also been successfully used in mice. 
  The two-kidney, two-clip and one-kidney, one-clip mod-
els are volume-dependent models of hypertension [7, 8], 
with the former the animal equivalent of bilateral renal artery 
stenosis in humans. It has been shown to be less dependent 
on the activation of the renin-angiotensin system (RAS) than 
the two-kidney, one-clip model. The latter is a pressure over-
load model, and dependent on activation of the RAS and 
vasoconstriction [7]. It is therefore sensitive to antagonists of 
the RAS. It is also sensitive to changes in dietary sodium, 
with a high sodium intake augmenting hypertension, and 
restriction of sodium reducing it [8]. It responds to calcium 
antagonists and vasodilators, but not to diuretics, beta-
blockers and endothelin antagonists [4]. 
  Unilateral renal artery stenosis has been used in pigs to 
study oxidative stress in renovascular hypertension [25]. 
Stenosis was produced by inserting a local-irritant coil into 
the renal artery, which resulted in a gradual proliferative 
neointimal response and progressive luminal narrowing. The 
authors demonstrated that a moderate stenosis produced only 
a transient increase in RAS activity, with oxidative stress 
remaining active.  
  There have also been experimental models that did not 
depend on renal artery constriction. Page produced the “per-
inephritis-type” hypertension by wrapping kidneys in silk 
and cellophane, resulting in the growth of a capsule of con-
nective tissue, with compression of the renal parenchyma 
and subsequent ischaemia [26]. This was applied to dogs, 
cats, rabbits and cynomolgus monkeys [8], and has been 
shown to be dependent on the RAS and on endothelin-1. The 
method used by Grollman is similar; it is a two-kidney, one-
Figure-8 wrap model [27], which has been used to study 
angiotensin in Sprague-Dawley rats [28]. The renal wrapping 
method has also been used in dogs to study diastolic heart 
failure [29].  
  Finally, the reduced renal mass method has been used 
less often to study renal hypertension; in this process 75% of the 
renal tissue is removed [30]. Nephrectomy models are more 
commonly used to study non-hypertensive cardiovascular 
disease in renal impairment. This model has been used in 
combination with a high salt diet, for example, to study the 
regulatory role of substance P in Sprague-Dawley rats [31]. 
URAEMIC CARDIOMYOPATHY: AN EXAMPLE OF 
LESSONS LEARNED  
  The subject of a uraemic cardiomyopathy occurring in-
dependently of hypertension and thus of afterload has been a 
contentious one. Clearly, chronic renal disease and athero-
sclerotic cardiovascular disease share certain risk factors, 
such as diabetes and hypercholesterolaemia. Yet coronary 
artery disease only accounts for half of the cardiac mortality 
of patients with end-stage renal failure [1]. Uraemic patients 
often die of congestive cardiac failure, sudden cardiac death, 
or uraemic cardiomyopathy. The cardiac findings associated 
with uraemia comprise of predominantly left ventricular   
hypertrophy, as well as, left ventricular dilatation and   
systolic dysfunction [32]. A similar fibrosis is not seen in 
other organs of animals with chronic renal failure. 
  Due to the controversy surrounding uraemic cardiomy-
opathy, a multitude of papers have been devoted to using 
animal models in the study of this condition. Most of these 
experiments have used the 5/6 nephrectomy model, in which 
the rat is anaesthetised and one kidney is removed. After an 
interval of 1-2 weeks, 2/3 of the contralateral kidney is de-
stroyed either by actual removal of renal tissue, or by infarc-
tion via ligation of two or three branches of its renal artery 
[33, 34]. 
 Perez-Ruiz  et al. highlighted a forgotten technique to 
study uraemic cardiomyopathy [35]. This method involves 
tying off the renal parenchyma in both renal poles. The 
authors claim that this method shares the advantages of the 
nephrectomy model, such as the reproducibility and homo-
geneity, while avoiding excessive bleeding, an advantage 
seen in the infarction technique. 
  Non-interventional studies of the heart in chronic renal 
failure have been performed, using the normotensive Zucker 
obese rat. This animal develops renal failure secondary to 
structural abnormalities, obesity and glucose intolerance, but 
not diabetes or hypertension. This allowed the study of a 
non-surgical uraemic cardiomyopathy; indeed, left ventricu-
lar hypertrophy was evident at 13 months [36]. 
Changes in Uraemia: Myocardial Hypertrophy 
 According  to  Rambausek  et al. [37], the first recorded 
increase in heart weight secondary to experimental renal 
failure was in 1879 [38]. However it was the study by   
Rambausek  et al. of subtotally nephrectomised Sprague-
Dawley rats  that provided the first clear insight into the   
independence of this process of blood pressure [37]. In their 
experiments, they found an increase in dry, de-fatted heart 
weight in the experimental group (after a range of 14-21 
days of uraemia) compared to controls (sham operated rats), 
despite beta adrenoceptor blockade, alpha-1 adrenoceptor 
blockade, and pharmacological normalisation of blood   
pressure with hydralazine or furosemide. The authors also 
demonstrated a shift from V3 to V1 isomyosin (with a faster 
contractile response) in the experimental group, which   
correlated with creatinine levels. 
  These results were reproducible, and experimental evi-
dence of myocardial hypertrophy secondary to chronic renal 
failure has subsequently become abundant [39]. There has 
continued to be some contention regarding the role of blood 
pressure in uraemic cardiomyopathy. Fabris et al. demon-
strated that the left ventricular weight of 5/6 nephrectomised 
Wistar hypertensive rats given only drinking water was 
greater than in rats given lisinopril, which were subsequently 
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between blood pressure and the degree of ventricular hyper-
trophy is intriguing, the limitations of this study were con-
siderable: there were no sham-operated controls; the weights 
measured were of wet, freshly dissected hearts; and angio-
tensin converting enzyme (ACE) inhibitors have complex 
effects on cardiac morphology, not merely acting via their 
antihypertensive effects. Clearly, blood pressure control is 
important in preventing cardiovascular disease in patients 
with chronic renal impairment, but the authors themselves 
acknowledged that there are other mechanisms at play. 
Myocardial Interstitial Fibrosis, Cardiac Compliance 
and Vascular Architecture 
  Using subtotally nephrectomised Sprague-Dawley rats, 
Mall et al. [40] showed that the increase in total heart weight 
demonstrated by Rambausek et al. [37] after 21 days of 
uraemia (as well as an increase in both right and left ven-
tricular weight) was secondary to an increase in true intersti-
tial volume, both cellular and non-cellular, with increased 
deposition of collagen. This was associated with activated 
interstitial cells, and a reduced capillary cross-sectional area. 
In 1992, this latter point was confirmed using stereological 
techniques to analyse perfusion-fixed hearts of subtotally 
nephrectomised Sprague-Dawley rats [41]. Uraemia resulted 
in increased blood pressure and reduced capillary length per 
unit myocardial volume, as well as reduced capillary luminal 
surface density and volume density, compared to control 
rats. The same group found a blood pressure-independent 
increase in the wall to lumen ratio of intramyocardial arter-
ies, and in the aorta media thickness of subtotally nephrec-
tomised rats [42]. The intramyocardial arterial wall thicken-
ing has been found to be due to hypertrophy rather than   
hyperplasia, independent of blood pressure [43]. 
  These architectural changes were reported again in 1996 
[44]. In that experiment, nephrectomised Sprague-Dawley 
rats were given ramipril, nifedipine or moxonidine to nor-
malise blood pressure; these drugs had differential effects on 
the above architectural changes, and also acted to  prevent 
these changes. 
  The different changes in interstitial and capillary density 
in uraemic cardiomyopathy have not yet been explained, but 
the role of growth factors  such as basic fibroblast growth 
factor (BFGF) and vascular endothelial growth factor 
(VEGF) has been proposed [44]. The reduced capillarisation 
was not seen in skeletal muscle (psoas) of nephrectomised 
rats [45], although blood pressure was not corrected in the 
experiment. 
  The above findings [40] were not seen when one-clip, 
two-kidney rat models of renovascular hypertension were 
studied. It was suggested that the consequences of the fibro-
sis produced in the nephrectomised rats would equate to   
direct, negative effects on cardiac compliance in uraemic 
patients, as well as resulting in altered electrical excitation 
pathways, a potential cause of the sudden cardiac death   
so often seen in renal patients. The electrophysiology of 
uraemic rats, both of isolated myocytes and the whole   
left ventricle, was later studied using a whole-cell patch-
clamp by Donohoe et al. [46], who found altered cardiac 
transient outward K
+ current resulting in shorter action   
potentials. 
Reduced Cardiac Chronotropic and Inotropic Respon- 
siveness in Uraemia  
  To study cardiac function in uraemia, bilaterally nephrec-
tomised rats have been treated with ACE inhibitors, mus-
carinic antagonists and ganglionic blockers [47], and chal-
lenged with intravenous isoprenaline. Uraemic rats showed a 
lower maximal response in heart rate, but no difference in 
blood pressure. Intravenous forskolin led to a lower maximal 
response in heart rate in the experimental rats, independent 
of receptor activity. This was attributed to reduced adenylate 
cyclase
 activity. Similarly, reduced cardiac beta-adrenocep- 
tor responsiveness was demonstrated in uraemic Wistar rats 
[48]. This time the inotropic responsiveness was due to re-
duced isoprenaline-induced activation of adenylate cyclase, 
potentially by uncoupling or inhibition; muscarinic receptor 
function was unaltered. 
Cardiac Function and Energetics in Uraemia  
  The above experiments provided some insight into the 
structural changes seen in uraemic hearts. They were fol-
lowed by a study using the subtotal (5/6) nephrectomy model 
on Wistar rats, in which the authors focused on the mechani-
cal effects of these structural changes in vitro, thereby re-
moving neurohormonal influences on cardiac contractility 
[3]. Four weeks after surgery, isolated perfusing working 
heart preparations demonstrated reduced cardiac output. 
However, blood pressure was not controlled during the four 
weeks post-operatively, and could have contributed to the 
effects. An increased susceptibility to ischaemic damage was 
also shown via decreased phosphocreatine content, and an 
increased release of inosine (a marker of ischaemic damage). 
These hearts failed in response to increases in calcium; the 
authors proposed that impaired cytosolic calcium control 
played a role in the relationship between renal failure and 
impaired cardiac function. 
 This  in vitro experiment demonstrated the fact that im-
paired cardiac function was independent of circulating urea 
and creatinine, as the hearts were perfused with physiologi-
cal saline, with no effect from the addition of urea and 
creatinine. The opposite has been shown in spontaneously 
beating mouse cardiac myocytes [49], in response to sera 
from patients on haemodialysis for chronic renal failure. 
Urea, creatinine, and combinations of the two reduced the 
cardiac inotropy and resulted in arrhythmias and asynchro-
nies. 
  Using subtotally nephrectomised Sprague-Dawley rats, 
Reddy et al. demonstrated that early experimental uraemia 
was associated with cardiac hypertrophy with normal func-
tion, and normal myocardial carnitine levels in the presence 
of serum carnitine deficiency [50]. As carnitine plays an im-
portant role in myocardial energy metabolism, they postu-
lated that tissue carnitine stores served to maintain cardiac 
metabolism in early uraemia. 
  These experiments make a good case for uraemic car-
diomyopathy to be a distinct entity from hypertensive car-
diac dysfunction and atherosclerotic cardiac disease secon-
dary to the risk factors common to both heart and kidney 
disease. The cause of this phenomenon is still controversial, 
with parathyroid hormone (PTH), angiotensin II, marino-
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(GH) all having been put forward as likely contributors to 
the process.  
The Role of Calcium in Uraemic Cardiomyopathy  
  Calcium ions play a crucial role in cardiac physiology, 
particularly in myocardial excitation-contraction coupling 
[51]. Therefore, PTH was one of the first culprits to be sus-
pected of playing a role in the pathophysiology of uraemic 
cardiomyopathy; this was as early as 1984 [52]. 
  As reviewed by Rostand and Drüeke [51], there are nu-
merous theories pertaining to the mechanisms whereby PTH 
could act as an intermediary between renal impairment and 
cardiomyopathy. These include direct trophic effects on 
myocytes and interstitial fibroblasts, and indirect effects via 
anaemia or large and small vessel changes. Rostand and 
Drüeke suggest an increase in blood pressure via hypercal-
caemia, but the effects on the heart appear to be independent 
of blood pressure [42]. 
 Rambausek  et al. [37] noted increased cardiac calcium 
content in experimental rats, and that an increase in heart 
weight still occurred after parathyroidectomy with calcium 
supplementation. This was followed in the 1990s by in vitro 
experiments that demonstrated; an increased cytosolic cal-
cium concentration in isolated rat myocytes in response to 
PTH [53], a reduced expression of PTH-related peptide re-
ceptor mRNA in rat hearts secondary to hyperparathyroidism 
due to chronic renal failure [54], and increased force and 
frequency of contraction of isolated, beating rat cardiomyo-
cytes [51, 55]. 
  Subsequent to “chance observations” in the laboratory, 
Amann et al. [56-58] argued for the role of PTH in the wall 
thickening of intramyocardial arterioles and for fibroblast 
activation and subsequent cardiac fibrosis. Through the use 
of subtotal nephrectomy, parathyroidectomy and calcimimet-
ics in rats, they were able to control the doses of PTH re-
ceived (though they did not measure the serum PTH). Abol-
ishing hyperparathyroidism using these methods prevented 
the cardiac fibrosis and capillary changes normally seen in 
nephrectomised rats, which was independent of blood pres-
sure. 
  This hypothesis has already been taken from the bench to 
the bedside, such as in the large retrospective study of 
haemodialysis patients in the USA, which found higher rates 
of cardiovascular events and death in association with disor-
ders of bone mineral metabolism, in particular with high 
phosphorus and calcium-phosphorus levels [59].  
The Renin-Angiotensin System (RAS) and Endothelin  
  Many studies have highlighted the importance of the 
RAS in the development of uraemic cardiomyopathy [33, 34, 
44, 60]. Tornig et al. [44] showed that in nephrectomised 
rats, ramipril, an ACE inhibitor, prevented the increased wall 
thickness of the intramyocardial arterioles, as well as the 
expansion of nonvascular cardiac interstitial volume and the 
aortic wall and lumen changes, but not the reduced capillary 
length density. The same group subsequently repeated these 
observations, and demonstrated that the beneficial effects of 
ramipril were prevented by the use of specific bradykinin B2 
receptor antagonists, suggesting a role for increased bradyki-
nin as a mediator for the effects of ramipril [34]. 
  Studies on mesenteric vessels from uraemic Sprague-
Dawley rats showed significant intimal cell proliferation and 
intimal thickening in resistance vessels in low-flow condi-
tions, with a reduction of these effects by an endothelin   
receptor antagonist [61]. These antagonists were also shown 
to prevent the interstitial changes of cardiac fibrosis [62].  
  The hypertrophy-sparing effects of angiotensin II recep-
tor blockade were also seen in subtotally nephrectomised 
Wistar rats by a Japanese group, who suggested that protein 
kinase C (PKC) and extracellular signal regulated kinase 
(ERK) activation were involved in the hypertrophy process 
[63]. They also showed that pitavastatin caused a reduction 
in angiotensin II-induced ERK activation and prevented the 
development of hypertrophy, without any change in blood 
pressure [64]. 
Oxidative Stress 
  The role of oxidative stress and nitric oxide (NO),   
proposed as a putative pathogenic mechanism for uraemic 
cardiomyopathy in as early as the 1990s [42, 65], was   
further investigated by Kalk et al. [66]. They used an NO-
independent activator of soluble guanylate cyclase in 5/6 
nephrectomised rats to demonstrate a reduction in cardiac 
hypertrophy and arterial wall thickness, with a concomitant 
reduction in blood pressure and renal disease progression. 
Michea et al. [67] have shown increased superoxide produc-
tion in 5/6 nephrectomised Sprague-Dawley rats, which is 
prevented by the administration of spironolactone, a miner-
alocorticoid receptor antagonist. Upregulation of the pro-
oxidant pathway in 5/6 nephrectomised rats has also been 
reversed by exercise on running wheels [68]. 
Growth Hormone (GH) 
  The effect of GH on the heart was studied in 5/6 nephrec-
tomised Sprague-Dawley rats [69]. Low dose GH was found 
to prevent the reduced capillary length density and increased 
fibroblast volume density, with reduced collagen and trans-
forming growth factor-beta (TGF-beta); aortic abnormalities 
were not affected. High-dose GH was found to worsen 
uraemic cardiomyopathy. 
The Role of Cardiotonic Steroids 
  A group from the University of Toledo postulated a role 
for digitalis-like substances, or cardiotonic steroids, in the 
pathogenesis of uraemic cardiomyopathy, in particular MBG 
[70],  via the plasmalemmal  sodium potassium ATPase 
(Na
+/K
+-ATPase). Subtotally nephrectomised Sprague-
Dawley rats were immunised against MBG, while sham-
operated received MBG infusions. These infusions resulted 
in cardiac fibrosis, oxidative stress, and reduced expression 
of the cardiac sarcoplasmic reticulum ATPase, whereas, im-
munisation against MBG produced the reverse effect. This 
was followed by in vitro studies showing that MBG stimu-
lates fibroblast collagen production, accounting for the car-
diac fibrosis [71]. 
The Sodium Potassium ATPase (Na
+/K
+-ATPase) 
  Previous studies have mostly used the method of renal 
decapsulation as sham-operated controls. Kennedy et al. [72] 
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tomy to rats that underwent suprarenal aortic banding. Both 
experimental groups developed hypertension to the same 
extent, but the nephrectomised rats developed greater cardiac 
hypertrophy. The nephrectomised rats also exhibited down-
regulation of cardiac Na
+/K
+-ATPase, impaired myocyte 
contractile function, and abnormal cell calcium cycling. The 
effect of uraemia on the Na
+/K
+-ATPase pump has been 
variable in different experiments, leaving the role of this 
molecule uncertain. Kennedy et al. suggest that both systolic 
function and diastolic function are abnormal, but that the 
systolic function is normal in vivo because it is masked by 
circulating digitalis-like substances in uraemia. 
Animal Models in Uraemic Cardiomyopathy 
  Nearly all the animal models of uraemic cardiomyopathy 
have involved the use of rats. However, Kennedy et al. per-
formed a 5/6 nephrectomy on CD1 mice, resulting in hyper-
tension, cardiac enlargement and fibrosis, similar to the rat 
models [73]. As the karyotype of the mouse is well known, 
this murine model offers opportunities for the use of genetic 
manipulation in the study of uraemic cardiomyopathy. In-
deed, the same group have already taken this opportunity 
[74], by studying mice with knockdown of Friend leukaemia 
integration-1 transcription factor (Fli-1) subject to 5/6 
nephrectomy. These mice demonstrated a greater degree of 
cardiac fibrosis than the wild type. This study also supports 
the above-mentioned role of MBG by demonstrating MBG-
induced translocation of PKC, resulting in decreases in Fli-1 
expression. 
 Bro  et al. [75] have also exploited the mouse genome, by 
using apolipoprotein E deficient C57BL/6 mice, which are 
resistant to the development of hypertension post-subtotal 
nephrectomy, to study the effect of uraemia on the heart, 
independently of blood pressure. These mice did not develop 
any defects in cardiac structure or function post-
nephrectomy. However, Siedlecki et al. [76] demonstrated 
that nephrectomised 129/SvJ mice developed histological 
signs of uraemic cardiomyopathy without hypertension or 
volume overload.  
VASCULAR CALCIFICATION IN CHRONIC RENAL 
FAILURE  
  Mouse models, as well as rat models, have been exten-
sively used in the study of vascular calcification in chronic 
renal failure [77]. Calcification of uraemic vessels is com-
mon, and associated with a greater cardiovascular mortality 
[78]. A review of animal models of vascular calcification 
already exists [77], thus, the present review focuses briefly 
on animal models of uraemic vascular calcification. 
  Knockout mouse models have been used to study the 
pathophysiology of vascular calcification. For example, stud-
ies have been used to demonstrate that low-density-
lipoprotein (LDL)-receptor knockout and a high cholesterol 
diet results in increased calcification of the intima and media 
of the aorta [79, 80]. The 5/6 nephrectomy rat model has 
been used in pharmacological studies, in order to demon-
strate the effects of calcitriol on vascular calcification in 
uraemia [78], and to study the potential use of vitamin D 
analogues such as 22-oxacalcitriol (OCT). For example, 
Hirata  et al. [81] demonstrated that OCT was effective in 
suppressing PTH in uraemic Sprague-Dawley rats, while 
producing less vascular calcification. Tamura et al. [82] used 
the same model in Wistar–Imamichi rats to show that the 
bisphosphonate etidronate prevents calcification of the aorta 
in renal failure. 
DE NOVO CARDIOMYOPATHY AFTER RENAL 
TRANSPLANTATION  
  Although renal transplants have been shown to amelio-
rate cardiovascular disease progression [83], human studies 
have highlighted a problem of new congestive cardiac failure 
in many patients post-renal transplantation [84, 85]. Few 
animal models have been used to provide insight into the 
pathological processes involved. Baumann et al. [2] ortho-
topically transplanted kidneys, under ciclosporin immuno-
suppression, from Fisher rats into Lewis rats, which had their 
native kidneys removed. This resulted in increased left ven-
tricular mass at 24 weeks post-transplant; this effect was 
dampened in transplanted rats given the angiotensin receptor 
blocker candesartan. However, controls consisted of un-
treated rats, i.e. rats not subjected to surgery or to pharma-
cological agents. Although it would appear that this model 
offers an opportunity to study the so-called transplantation-
induced cardiomyopathy, more convincing control groups 
are needed. 
CONCLUSIONS 
  Experimental models have played a crucial role in the 
study of the complex interplay between the heart and the 
kidney in chronic renal disease. In view of the numerous 
differences in animal and human anatomy, physiology and 
pathology, the results of these experiments should be inter-
preted with caution, but in some areas, these studies have led 
directly to advances in therapeutics. Conditions such as 
uraemic cardiomyopathy and transplantation-induced car-
diomyopathy are still poorly understood, and it is clear that 
animal models will continue to provide hitherto unforeseen 
insights into their pathophysiology.  
ABBREVIATIONS 
ACE  =   Angiotensin converting enzyme  
BFGF  =  Basic fibroblast growth factor 
ERK  =  Extracellular signal regulated kinase 
Fli-1  =  Friend leukaemia integration-1 transcription 
factor 
GH =  Growth  hormone 
LDL =  low-density-lipoprotein 
MBG =  Marinobufagenin 
NO =  Nitric  oxide 
PTH =  Parathyroid  hormone 
PKC  =  Protein kinase C 
RAS =  Renin-angiotensin  system 
TGF-  =  Transforming growth factor-beta 
VEGF  =  Vascular endothelial growth factor 
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